The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer

Main Article Content

Aurelio Bartolome Castrellon (1*), Ihor Pidhorecky (2), Vicente Valero (3), Luis Estuardo Raez (4)

1 Breast Cancer Research, Memorial Cancer Institute, Memorial Healthcare System, Hollywood, FL, United States.
2 Surgical Oncology Services & Pancreaticobiliary Center, Memorial Cancer Institute, Memorial Healthcare System, Hollywood, FL, United States.
3 Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
4 Hematology/Oncology and Medical Director of Memorial Cancer Institute, Memorial Healthcare System, Hollywood, FL, United States.
(*) Corresponding Author:
Aurelio Bartolome Castrellon
acastrellon@mhs.net

Abstract

Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

How to Cite
Castrellon, A., Pidhorecky, I., Valero, V., & Raez, L. (2017). The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer. Oncology Reviews, 11(1). https://doi.org/10.4081/oncol.2017.324
Author Biographies

Aurelio Bartolome Castrellon, Breast Cancer Research, Memorial Cancer Institute, Memorial Healthcare System, Hollywood, FL

Director of Breast Cancer Research

Ihor Pidhorecky, Surgical Oncology Services & Pancreaticobiliary Center, Memorial Cancer Institute, Memorial Healthcare System, Hollywood, FL

Medical Director, Surgical Oncology Services & Pancreaticobiliary Center

Vicente Valero, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Deputy Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine

Luis Estuardo Raez, Hematology/Oncology and Medical Director of Memorial Cancer Institute, Memorial Healthcare System, Hollywood, FL

Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute